Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
Dificid fidaxomicin Clostridium difficile infection Active
TBC ivosidenib Acute myeloid leukemia (AML) Received
Keytruda pembrolizumab Gastric or gastroesophageal junction (GEJ) adenocarcinoma Received
TBC danicopan Paroxysmal nocturnal hemoglobinuria (PNH) Pending
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Pending
TBC eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Pending
N/A nab-paclitaxel Gastrointestinal cancer Pending
Alecensaro alectinib ALK-positive NSCLC Pending
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Pending